Company ALK-Abelló A/S

Equities

ALK B

DK0061802139

Pharmaceuticals

Market Closed - Nasdaq Copenhagen 11:59:49 2024-03-18 am EDT 5-day change 1st Jan Change
129.2 DKK +1.41% Intraday chart for ALK-Abelló A/S -0.39% +27.67%

Business Summary

ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company's allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.

Number of employees: 2,824

Sales per Business

DKK in Million2022Weight2023Weight Delta
Sublingual Immunotherapy-Tablets
47.6 %
2,102 46.6 % 2,296 47.6 % +9.23%
Subcutaneous Immunotherapy/Sublingual Immunotherapy-Drops
40.2 %
1,748 38.7 % 1,939 40.2 % +10.93%
Other
12.2 %
661 14.7 % 589 12.2 % -10.89%

Sales per region

DKK in Million2022Weight2023Weight Delta
Europe
38.5 %
2,939 65.2 % 1,858 38.5 % -36.79%
North America
15.8 %
857 19.0 % 763 15.8 % -11.00%
Germany
14.7 %
-- 708 14.7 % -
International
13.1 %
596 13.2 % 630 13.1 % +5.70%
France
11.3 %
-- 547 11.3 % -
United States
3.0 %
-- 145 3.0 % -
Denmark
2.2 %
119 2.6 % 104 2.2 % -12.61%
Japan
1.5 %
-- 70 1.5 % -

Managers

Managers TitleAgeSince
Chief Executive Officer 45 Dec. 31
Director of Finance/CFO 52 23-05-31
Chief Tech/Sci/R&D Officer - 23-02-28
Director/Board Member 48 -
Director/Board Member 55 -
Public Communications Contact - 19-09-30
Investor Relations Contact - -
Corporate Officer/Principal - 94-04-30
Corporate Officer/Principal 53 12-05-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 57 21-03-17
Chairman 63 20-03-10
Director/Board Member 64 15-03-11
Director/Board Member 64 13-12-31
Director/Board Member 68 21-03-17
Director/Board Member 55 -
Director/Board Member 61 22-03-15
Director/Board Member 48 -
Director/Board Member 52 18-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 10 1,841,520 0 0 58.99 %
Stock B 10 18,415,200 0 0
Stock C 1 202,567,200 131,435,987 ( 64.89 %) 1,634,673 ( 0.8070 %)

Shareholders

NameEquities%Valuation
Lundbeck Foundation
34.31 %
69,496,540 34.31 % 1 296 M kr
ATP Fondsmaeglerselskab A/S
17.50 %
35,456,260 17.50 % 661 M kr
ATP Arbejdsmarkedets Tillægspension
5.542 %
11,226,329 5.542 % 209 M kr
Danske Bank A/S (Investment Management)
1.381 %
2,798,131 1.381 % 52 M kr
H. Lunden Kapitalförvaltning AB
0.8437 %
1,709,120 0.8437 % 32 M kr
1,634,673 0.8070 % 30 M kr
Industriens Pensionsforsikring A/S
0.4601 %
932,100 0.4601 % 17 M kr
MP Investment Management A/S
0.4537 %
919,040 0.4537 % 17 M kr
Pareto Asset Management AS
0.2683 %
543,500 0.2683 % 10 M kr
Banque Internationale À Luxembourg SA (Denmark)
0.2202 %
446,120 0.2202 % 8 M kr
NameEquities%Valuation
Lundbeck Foundation
100.00 %
18,414,400 100.00 % 344 M kr
NameEquities%Valuation
Lundbeck Foundation
100.00 %
1,841,440 100.00 % 34 M kr

Holdings

NameEquities%Valuation
1,634,673 0.81% 30,494,531 $

Company contact information

ALK-Abello A/S

Bøge Allé 6-8

2970, Hørsholm

+45 45 74 75 76

http://www.alk.net
address ALK-Abelló A/S(ALK B)

Sales per Business

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
129.2 DKK
Average target price
125 DKK
Spread / Average Target
-3.25%
Consensus